tetano
Editor, Senior Moderator
Front Immunol
. 2023 Jun 13;14:1204543.
doi: 10.3389/fimmu.2023.1204543. eCollection 2023. A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells
Alexandra Kegler[SUP] 1 [/SUP], Laura Drewitz[SUP] 1 [/SUP], Claudia Arndt[SUP] 1 2 [/SUP], Cansu Daglar[SUP] 1 [/SUP], Liliana Rodrigues Loureiro[SUP] 1 [/SUP], Nicola Mitwasi[SUP] 1 [/SUP], Christin Neuber[SUP] 1 [/SUP], Karla Elizabeth González Soto[SUP] 1 [/SUP], Tabea Bartsch[SUP] 1 [/SUP], Larysa Baraban[SUP] 1 [/SUP], Holger Ziehr[SUP] 3 [/SUP], Markus Heine[SUP] 3 [/SUP], Annabel Nieter[SUP] 3 [/SUP], Andres Moreira-Soto[SUP] 4 [/SUP], Arne Kühne[SUP] 4 [/SUP], Jan Felix Drexler[SUP] 4 [/SUP], Barbara Seliger[SUP] 5 6 [/SUP], Markus Laube[SUP] 7 [/SUP], Domokos Máthé[SUP] 8 9 10 [/SUP], Bernadett Pályi[SUP] 11 [/SUP], Polett Hajdrik[SUP] 8 [/SUP], László Forgách[SUP] 12 [/SUP], Zoltán Kis[SUP] 11 [/SUP], Krisztián Szigeti[SUP] 8 [/SUP], Ralf Bergmann[SUP] 1 8 [/SUP], Anja Feldmann[SUP] 1 13 14 [/SUP], Michael Bachmann[SUP] 1 13 14 [/SUP]
Affiliations
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to millions of infections and deaths worldwide. As this virus evolves rapidly, there is a high need for treatment options that can win the race against new emerging variants of concern. Here, we describe a novel immunotherapeutic drug based on the SARS-CoV-2 entry receptor ACE2 and provide experimental evidence that it cannot only be used for (i) neutralization of SARS-CoV-2 in vitro and in SARS-CoV-2-infected animal models but also for (ii) clearance of virus-infected cells. For the latter purpose, we equipped the ACE2 decoy with an epitope tag. Thereby, we converted it to an adapter molecule, which we successfully applied in the modular platforms UniMAB and UniCAR for retargeting of either unmodified or universal chimeric antigen receptor-modified immune effector cells. Our results pave the way for a clinical application of this novel ACE2 decoy, which will clearly improve COVID-19 treatment.
Keywords: ACE2 decoy; COVID-19; SARS–CoV–2; T-cell based immunotherapy; adapter CAR platform; bispecific antibody.
. 2023 Jun 13;14:1204543.
doi: 10.3389/fimmu.2023.1204543. eCollection 2023. A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells
Alexandra Kegler[SUP] 1 [/SUP], Laura Drewitz[SUP] 1 [/SUP], Claudia Arndt[SUP] 1 2 [/SUP], Cansu Daglar[SUP] 1 [/SUP], Liliana Rodrigues Loureiro[SUP] 1 [/SUP], Nicola Mitwasi[SUP] 1 [/SUP], Christin Neuber[SUP] 1 [/SUP], Karla Elizabeth González Soto[SUP] 1 [/SUP], Tabea Bartsch[SUP] 1 [/SUP], Larysa Baraban[SUP] 1 [/SUP], Holger Ziehr[SUP] 3 [/SUP], Markus Heine[SUP] 3 [/SUP], Annabel Nieter[SUP] 3 [/SUP], Andres Moreira-Soto[SUP] 4 [/SUP], Arne Kühne[SUP] 4 [/SUP], Jan Felix Drexler[SUP] 4 [/SUP], Barbara Seliger[SUP] 5 6 [/SUP], Markus Laube[SUP] 7 [/SUP], Domokos Máthé[SUP] 8 9 10 [/SUP], Bernadett Pályi[SUP] 11 [/SUP], Polett Hajdrik[SUP] 8 [/SUP], László Forgách[SUP] 12 [/SUP], Zoltán Kis[SUP] 11 [/SUP], Krisztián Szigeti[SUP] 8 [/SUP], Ralf Bergmann[SUP] 1 8 [/SUP], Anja Feldmann[SUP] 1 13 14 [/SUP], Michael Bachmann[SUP] 1 13 14 [/SUP]
Affiliations
- PMID: 37383226
- PMCID: PMC10293748
- DOI: 10.3389/fimmu.2023.1204543
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to millions of infections and deaths worldwide. As this virus evolves rapidly, there is a high need for treatment options that can win the race against new emerging variants of concern. Here, we describe a novel immunotherapeutic drug based on the SARS-CoV-2 entry receptor ACE2 and provide experimental evidence that it cannot only be used for (i) neutralization of SARS-CoV-2 in vitro and in SARS-CoV-2-infected animal models but also for (ii) clearance of virus-infected cells. For the latter purpose, we equipped the ACE2 decoy with an epitope tag. Thereby, we converted it to an adapter molecule, which we successfully applied in the modular platforms UniMAB and UniCAR for retargeting of either unmodified or universal chimeric antigen receptor-modified immune effector cells. Our results pave the way for a clinical application of this novel ACE2 decoy, which will clearly improve COVID-19 treatment.
Keywords: ACE2 decoy; COVID-19; SARS–CoV–2; T-cell based immunotherapy; adapter CAR platform; bispecific antibody.